{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:10:06Z","timestamp":1778202606728,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.urolonc.2026.03.009","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:35:42Z","timestamp":1776288942000},"page":"135-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An integrated restricted mean survival time-based evaluation of efficacy, toxicity, and cost in first-line immunotherapy regimens for metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"44","author":[{"given":"Yudai","family":"Ishiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reynier D Rodriguez","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Kanumuambidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bandyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-2839","authenticated-orcid":false,"given":"K.C.","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.urolonc.2026.03.009_bib0001","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European Association of Urology Guidelines on renal cell carcinoma: the 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"issue":"10189","key":"10.1016\/j.urolonc.2026.03.009_bib0002","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.urolonc.2026.03.009_bib0003","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.03.009_bib0004","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.03.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102994","article-title":"Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial","volume":"9","author":"Powles","year":"2024","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.urolonc.2026.03.009_bib0006","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III checkMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.03.009_bib0007","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.03.009_bib0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eururo.2023.01.001","article-title":"Outcomes for international metastatic renal cell carcinoma database consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma","volume":"84","author":"Ernst","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.03.009_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN Guidelines(R) insights: kidney Cancer, version 2.2024","volume":"22","author":"Motzer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.urolonc.2026.03.009_bib0010","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1016\/j.clgc.2023.03.005","article-title":"Identifying the needs of health care providers in advanced first-line renal cell carcinoma: a mixed-methods research","volume":"21","author":"Lazure","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2026.03.009_bib0011","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdy462","article-title":"Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment","volume":"30","author":"Weir","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.03.009_bib0012","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jamaoncol.2017.2797","article-title":"Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio","volume":"3","author":"Pak","year":"2017","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.urolonc.2026.03.009_bib0013","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2015.64.2488","article-title":"Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials","volume":"34","author":"Trinquart","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.03.009_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.955894","article-title":"Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation","volume":"12","author":"Nocera","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.03.009_bib0015","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/biom.12772","article-title":"Analysis of restricted mean survival time for length-biased data","volume":"74","author":"Lee","year":"2018","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.urolonc.2026.03.009_bib0016","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urolonc.2026.03.009_bib0017","unstructured":"U.S. Centers for Medicare & Medicaid Services. Medicare Part B drug average sales price (ASP) pricing files. Accessed July, 2025. https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price."},{"key":"10.1016\/j.urolonc.2026.03.009_bib0018","unstructured":"(HCUP) HCaUP. Healthcare Cost and Utilization Project (HCUP). Agency for healthcare research and quality. 2021. https:\/\/www.hcup-us.ahrq.gov\/"},{"issue":"3","key":"10.1016\/j.urolonc.2026.03.009_bib0019","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3111\/13696998.2014.985789","article-title":"Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US","volume":"18","author":"Perrin","year":"2015","journal-title":"J Med Econ"},{"key":"10.1016\/j.urolonc.2026.03.009_bib0020","unstructured":"U.S. Department of Health and Human Services NCI. Common terminology Criteria for adverse events (CTCAE) version 5.0. National Cancer Institute. Updated November 2017. Accessed June 23, 2025, 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development"},{"key":"10.1016\/j.urolonc.2026.03.009_bib0021","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.03.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0643","article-title":"Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer","volume":"3","author":"Marschner","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.urolonc.2026.03.009_bib0023","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1200\/OP.22.00447","article-title":"Cost-effectiveness analysis of six immunotherapy-based regimens and Sunitinib in metastatic renal cell carcinoma: a public payer perspective","volume":"19","author":"Yoo","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"10.1016\/j.urolonc.2026.03.009_bib0024","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.2016.72.2124","article-title":"Trajectories of injectable cancer drug costs after launch in the United States","volume":"36","author":"Gordon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.urolonc.2026.03.009_bib0025","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.urolonc.2026.03.009_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005445","article-title":"Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"10","author":"Rini","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2026.03.009_bib0027","doi-asserted-by":"crossref","first-page":"S683","DOI":"10.1016\/j.annonc.2021.08.056","article-title":"660P Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): outcomes in subgroups and toxicity update","volume":"32","author":"Choueiri","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.03.009_bib0028","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11523-024-01069-6","article-title":"Survival impact of glucocorticoid administration for adverse events during Immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma","volume":"19","author":"Yoshino","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.urolonc.2026.03.009_bib0029","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2017.10.009","article-title":"Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review","volume":"120","author":"Garant","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.03.009_bib0030","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1053\/j.seminoncol.2022.10.001","article-title":"IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: a structured systematic review over time","volume":"49","author":"Hoeh","year":"2022","journal-title":"Semin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926001158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926001158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:28:48Z","timestamp":1778200128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926001158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1078143926001158"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.03.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An integrated restricted mean survival time-based evaluation of efficacy, toxicity, and cost in first-line immunotherapy regimens for metastatic renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}